Piramal Pharma Solutions (PPS), has entered into a Master Services Agreement (MSA) with Plus Therapeutics, Inc. for Piramal to perform services related to the development, manufacture, and supply of Plus Therapeutics’ RNL-Liposome Intermediate Drug Product.

This MSA includes the transfer of analytical methods, development of microbiological methods, process transfer and optimization, intermediate drug product manufacturing, and stability studies. The transfer will be performed at PPS’ facility located in Lexington, KY. It’s anticipated that the MSA will lead to clinical and commercial supply agreements for the drug product.

PPS’ Lexington site provides formulation, development and manufacturing of sterile parenteral drug products with the capability to support New Chemical Entities (NCEs), generics, and molecules that might be following the 505(b)(2) regulatory pathway.

“This agreement represents another significant milestone for Plus, as we work to advance development of RNL as a novel treatment option for patients diagnosed with glioblastoma,” said Marc Hedrick M.D., President and Chief Executive Officer of Plus Therapeutics. “The team at PPS has the knowledge, experience and expertise to support our needs, both now and in the future as we advance RNL towards regulatory approval.”